GH-Axis Peptides and Blood Glucose: Why Growth Hormone Secretagogues Can Shift Insulin Sensitivity

Growth hormone is a counter-regulatory hormone, so peptides that raise GH output can transiently reduce insulin sensitivity and lift fasting glucose. This article explains the mechanism, what the research shows, and how physician-led protocols monitor for it.

By UAE Peptide Clinic Research Desk

Growth hormone secretagogues such as CJC-1295, Ipamorelin, Tesamorelin and Sermorelin are among the most frequently prescribed peptides in physician-led practice. They are usually discussed in terms of body composition, recovery and sleep. Far less often discussed is a well-established piece of endocrinology that sits underneath all of them: growth hormone is a counter-regulatory hormone. It opposes insulin. Anyone raising their GH output, by any route, should understand what that means for their blood glucose and why a good clinic monitors it.

Why growth hormone opposes insulin

Insulin lowers blood glucose by pushing it into muscle, liver and fat cells. Growth hormone does roughly the opposite. It increases hepatic glucose output, promotes lipolysis so that free fatty acids rise, and reduces glucose uptake in peripheral tissue. Those free fatty acids in turn interfere with insulin signalling in muscle, a mechanism sometimes called substrate competition. The net effect, documented in decades of clinical endocrinology, is that elevated GH produces a mild, dose-dependent state of insulin resistance.

This is not a flaw. It is the reason GH exists physiologically. The largest natural GH pulse occurs in the first hours of deep sleep, during an overnight fast, precisely when the body needs to mobilise stored fuel rather than store more of it. The peptides used clinically work by amplifying this same pulsatile release rather than replacing it, which is one reason their glycaemic effect is generally modest compared with exogenous recombinant GH.

What the research shows for secretagogues specifically

The clearest human data come from Tesamorelin. In its phase 3 trials, participants showed small increases in fasting glucose and HbA1c in the early weeks that largely attenuated by week 26, and the drug label still advises glucose monitoring throughout treatment. Ipamorelin and CJC-1295 have less trial data, but their mechanism is shared: more GH, more IGF-1, and the same counter-regulatory physiology. Research on GHRH analogues suggests the effect is more pronounced at higher doses, with continuous rather than pulsatile exposure, and in people who already carry insulin resistance.

• Fasting glucose may rise by a few tenths of a millimole per litre in the first four to eight weeks of a GH-axis protocol.
• HbA1c shifts, where they occur, tend to be small and often reverse as IGF-1 rises, since IGF-1 itself has insulin-like effects that partly offset GH.
• People with pre-existing impaired fasting glucose, central adiposity or a family history of type 2 diabetes are the group most likely to see a measurable change.
• Pulsatile dosing at night, before sleep and away from meals, appears to produce a smaller glycaemic footprint than daytime or post-meal dosing.

Growth hormone and insulin pull in opposite directions. A well-designed protocol respects that rather than ignoring it.

How physician oversight manages the risk

In practice this comes down to baseline testing, sensible dosing and a monitoring schedule. A pre-protocol panel should include fasting glucose, fasting insulin, HbA1c and ideally a calculated HOMA-IR score, alongside IGF-1. Those numbers establish where a patient starts, and they determine whether a GH-axis peptide is appropriate at all. A patient with an HbA1c already in the pre-diabetic range is usually better served by addressing metabolic health first, or by a peptide such as MOTS-C or AOD-9604 whose research profile points towards improved rather than reduced insulin sensitivity.

Once a protocol is under way, repeat testing at six to eight weeks catches any drift early. Dosing on the conservative end, cycling the protocol rather than running it indefinitely, and timing injections before sleep all reduce exposure. Anyone using a continuous glucose monitor for other reasons can share that data with their prescriber, though a single fasting glucose value is not something to act on alone: GH-axis peptides taken the night before will predictably raise the morning reading, and that alone does not indicate a problem.

Clinical nuance: medications and fasting

Patients already prescribed metformin, a GLP-1 receptor agonist, an SGLT2 inhibitor or insulin need their prescriber to know before any GH-axis peptide is started, because the interaction is real and the medication dose may need review. Extended fasting or very low carbohydrate eating alongside a GH secretagogue can also exaggerate the free fatty acid rise. None of this rules out treatment; it simply means the protocol is designed around the patient rather than the other way round.

If you're exploring GH-axis peptides as part of your protocol and want to understand how they fit with your metabolic health, our clinical team can review your case, including your blood glucose markers. Take the 2-minute quiz at /find-my-stack or book a free consultation at /book.